|
Group 1 (treated CaP)
|
No
|
No
|
No
|
|
Total (n = 11)
|
patients (%)
|
patients (%)
|
patients (%)
|
|
subtype 1 without recurrence (n = 5)
|
2 (40)
|
2 (40)
|
5 (100)
|
|
subtype 2 with recurrence (n = 6)
|
5 (83)
|
5 (83)
|
6 (100)
|
|
Gleason score
| | | |
|
4–7 (n = 9)
|
4 (44.44)
|
6 (66.66)
|
9 (100)
|
|
8 (n = 2)
|
2 (100)
|
2 (100)
|
2 (100)
|
|
TNM
| | | |
|
Organ-confined disease (n = 7)
| | | |
|
T2 N0 M0 (n = 7)
|
4 (57.14)
|
5 (71.42)
|
7 (100)
|
|
Extraprostatic disease (n = 4)
| | | |
|
T3 N0 M0 (n = 2)
|
1 (50)
|
1 (50)
|
2 (100)
|
|
T3 N1M0 and T3 N2M0 (n = 2)
|
2 (100)
|
1 (50)
|
2 (100)
|
|
Group 2 (untreated CaP)
| | | |
|
Total (n = 11)
| | | |
|
Gleason score
| | | |
|
6–7 (n = 11)
|
2 (18.18)
|
9 (81.81)
|
11 (100)
|
|
TNM
| | | |
|
Organ-confined disease (n = 11)
| | | |
|
T1 (n = 4)
|
0
|
3 (75
|
4 (100)
|
|
T2 (n = 7)
|
2 (28.6)
|
6 (85.7)
|
7 (100)
|
